The economic side of an oral sugar lowering therapy intensification by glucagon-like peptidt-1 receptor agonists
The effective control of Diabetes Mellitus (DM) is an actual problem from optimal expenditures of health care system point of view. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are one of the modern options for glycemia control in DM Type 2 and included in all current guidelines for the trea...
Main Authors: | S. K. Zyryanov, I. N. Dyakov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Izdatelstvo OKI
2022-02-01
|
Series: | Качественная клиническая практика |
Subjects: | |
Online Access: | https://www.clinvest.ru/jour/article/view/592 |
Similar Items
-
Pharmacoeconomic characteristics of agonists of receptors for glucagon-like peptide-1 and medicines on their base
by: I. N. Dyakov, et al.
Published: (2021-08-01) -
The pharmacoeconomic comparison of the fixed insulin glargine and lixisenatide combination with insulin degludec family in type 2 diabetes mellitus
by: I. N. Dyakov, et al.
Published: (2021-02-01) -
Economic evaluation of insulin therapy intensification for effective and safe control of diabetes mellitus type 2
by: A. S. Kolbin, et al.
Published: (2019-10-01) -
Economic analysis of Lixisenatide in Diabetes Mellitus Type 2
by: A. S. Kolbin, et al.
Published: (2018-05-01) -
Economic evaluation of the fixed combination of insulin glargine and lixisenatide in Diabetes Mellitus type 2
by: S. V. Nedogoda, et al.
Published: (2020-01-01)